Webb spots outsized early black hole & GSK hepatitis B drug boosts cures - News (May 29, 2026)

China’s brain implant milestone & South Africa’s twice-yearly HIV prevention - News (Jun 9, 2026)

Please support this podcast by checking out our sponsors: - KrispCall: Agentic Cloud Telephony - https://try.krispcall.com/tad [https://try.krispcall.com/tad] - Discover the Future of AI Audio with ElevenLabs - https://try.elevenlabs.io/tad [https://try.elevenlabs.io/tad] - Consensus: AI for Research. Get a free month - https://get.consensus.app/automated_daily [https://get.consensus.app/automated_daily] Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily [https://buymeacoffee.com/theautomateddaily] TODAY'S TOPICS: CHINA’S BRAIN IMPLANT MILESTONE - CHINA APPROVED THE NEO BRAIN-COMPUTER INTERFACE IMPLANT FOR COMMERCIAL SALE, A STEP BEYOND NEURALINK’S LIMITED TRIALS. KEYWORDS: BRAIN CHIP, BCI, PARALYSIS, APPROVAL, NEURAL DATA PRIVACY. SOUTH AFRICA’S TWICE-YEARLY HIV PREVENTION - SOUTH AFRICA BEGAN ROLLING OUT LENACAPAVIR, A TWICE-YEARLY HIV PREVENTION INJECTION, AIMING TO SOLVE DAILY-PILL ADHERENCE PROBLEMS. KEYWORDS: HIV, PREP, LENACAPAVIR, GLOBAL FUND, ACCESS GAP. GLP-1 DRUGS: BENEFITS AND RISKS - GLP-1 MEDICATIONS CONTINUE SPREADING BEYOND DIABETES INTO WEIGHT LOSS, WITH REPORTS OF IMPROVED MOBILITY BUT ALSO NAUSEA AND EMOTIONAL “FLATNESS” FOR SOME. KEYWORDS: GLP-1, SEMAGLUTIDE, TIRZEPATIDE, SIDE EFFECTS, AFFORDABILITY. CANCER SIGNALS TIED TO GLP-1S - EARLY ONCOLOGY ANALYSES SUGGEST GLP-1 USE MAY CORRELATE WITH LOWER CANCER RISK OR SLOWER PROGRESSION, BUT RESEARCHERS STRESS IT’S NOT PROOF YET. KEYWORDS: ASCO, CANCER RISK, INFLAMMATION, CORRELATION, CLINICAL STUDIES. OPENAI’S CONFIDENTIAL IPO FILING - OPENAI CONFIDENTIALLY FILED FOR AN IPO WHILE EXPLORING A SHARE SALE FOR EMPLOYEES, SPOTLIGHTING THE COST AND HYPE OF THE AI BOOM. KEYWORDS: OPENAI IPO, CHATGPT, DATA CENTERS, PROFITABILITY, TENDER OFFER. NUCLEAR RISKS AFTER NEW START - SIPRI WARNS NUCLEAR WEAPONS ARE REGAINING PROMINENCE AS NEW START EXPIRES AND MODERNIZATION ACCELERATES, RAISING MISCALCULATION RISKS. KEYWORDS: SIPRI 2026, WARHEADS, HIGH ALERT, ARMS CONTROL, CHINA BUILDUP. IRAN–ISRAEL CEASEFIRE AND HORMUZ - PRESIDENT TRUMP SAID A BROADER IRAN–ISRAEL DEAL COULD COME WITHIN DAYS, BUT THE CEASEFIRE REMAINS FRAGILE WITH RISKS TO THE STRAIT OF HORMUZ. KEYWORDS: CEASEFIRE, RETALIATION, HEZBOLLAH, HORMUZ, OIL SHIPPING. CHINA’S EXPORT SURGE AND SURPLUS - CHINA’S EXPORTS JUMPED IN MAY AS BUYERS RUSHED ORDERS AMID GEOPOLITICAL UNCERTAINTY, THOUGH ECONOMISTS WARN THE BOOST MAY FADE. KEYWORDS: EXPORTS, IMPORTS, TRADE SURPLUS, DEMAND, OVERCAPACITY CRITICISM. NVIDIA AND SK HYNIX AI MEMORY PUSH - NVIDIA AND SK HYNIX STRUCK A LONG-TERM PARTNERSHIP FOCUSED ON NEXT-GENERATION MEMORY AND FASTER CHIP-MAKING, REFLECTING AI INFRASTRUCTURE BOTTLENECKS. KEYWORDS: AI FACTORIES, MEMORY SUPPLY, SEMICONDUCTOR, MANUFACTURING AUTOMATION, SCALE. GLIOBLASTOMA FIGHT AND NEW RESEARCH - AUSTRALIA MOURNS CANCER RESEARCHER RICHARD SCOLYER, AS SCIENTISTS PUSH COMBINATION APPROACHES AGAINST GLIOBLASTOMA’S STUBBORN RESISTANCE. KEYWORDS: GLIOBLASTOMA, IMMUNOTHERAPY, VACCINE, BLOOD-BRAIN BARRIER, PERSISTOR CELLS. Episode Transcript China’s brain implant milestone Let’s start with that brain-tech milestone. China has approved a brain-computer interface implant called NEO for commercial sale after it completed clinical trials. The device is aimed at helping people with paralysis and spinal cord injuries, and reports suggest it’s headed toward wider rollout through China’s state healthcare system. What makes this especially notable is the timing: Neuralink is still in limited human testing and hasn’t reached broad approval. China’s faster move could give it an early advantage in setting standards—while also bringing big unresolved questions into sharper focus, like surgical safety, how the body reacts over time, and how to protect intensely personal neural data from misuse or hacking. South Africa’s twice-yearly HIV prevention Staying on health, South Africa has begun rolling out lenacapavir—an injectable HIV-prevention medicine given just twice a year. President Cyril Ramaphosa called it a turning point, and for a country carrying the world’s highest HIV burden, it’s easy to see why. The key appeal is simple: many people struggle to take a daily pill consistently, and prevention only works when it’s actually used. Trials in South Africa and Uganda showed very high protection, including a headline-making Johannesburg study that reported complete protection over a six-month period. But the rollout also highlights a familiar challenge—access. South Africa has funding to cover hundreds of thousands of people for a year, with the first doses going to facilities in the hardest-hit provinces and prioritized for groups at higher risk. Advocates say that’s still nowhere near enough for real population-level impact, arguing that millions of doses a year would be needed. And reaching some groups may be harder now, after U.S. aid cuts closed specialized clinics that people trusted for privacy and stigma-free care. The government says staff training and service changes are underway, but the test will be whether people feel safe enough to show up. GLP-1 drugs: benefits and risks Now to the GLP-1 wave—drugs originally built for diabetes that have become mainstream weight-loss treatments. A new U.S. profile highlights just how broad the conversation has become: one patient says an off-label GLP-1 eased severe joint inflammation quickly, and later helped drive major weight loss. Doctors point to potential upsides beyond the scale—better mobility, better overall health, and possibly fewer obesity-related complications over time. But it’s not a miracle with no trade-offs. Many patients still report unpleasant stomach side effects, and there’s growing discussion about something harder to quantify: some people say they feel less joy or interest in things they used to enjoy—an effect that may improve if dosing changes. Meanwhile, access remains a huge dividing line. Even with public programs moving toward coverage, many privately insured patients still face steep costs, and clinicians are experimenting informally with strategies like spacing doses farther apart to maintain results—ideas that now need proper trials to confirm what’s safe and effective. Cancer signals tied to GLP-1s Related to that, oncology researchers are increasingly asking whether GLP-1 drugs might be connected to cancer outcomes—not as a proven treatment, but as a possible protective factor. New analyses presented at a major cancer meeting suggest GLP-1 use is linked, in medical-record studies, to lower risk in several cancers and to slower disease progression in some groups. One dataset study found an association with reduced risk across multiple cancers, with some of the strongest signals reported in areas like breast and colorectal cancer. Another analysis found women taking GLP-1s were less likely to develop breast cancer. Important caveat: these findings are correlational. Medical databases can miss crucial details—like lifestyle changes, other illnesses, or why a particular patient was prescribed a drug in the first place. Still, the pattern is intriguing enough that researchers are now launching studies to look for biological clues beyond weight loss, including changes in inflammation and metabolism. OpenAI’s confidential IPO filing In Australia, the death of Richard Scolyer—former Australian of the Year—has refocused attention on glioblastoma, one of the most aggressive brain cancers. Despite huge progress in many other cancers, glioblastoma outcomes have barely improved for decades. The reason is brutal biology and brutal geography. These tumors are hard to remove cleanly without damaging essential brain function, they often resist standard drugs, and they tend to return. Researchers have been exploring new approaches, including the kind of personalized immunotherapy and vaccine strategy Scolyer himself pursued, which reportedly helped delay recurrence. The broader takeaway is that progress is coming, but likely through combination therapies rather than one single breakthrough—and that real gains will take sustained investment in a disease that has long been a graveyard for easy answers. Nuclear risks after New START Turning to business and tech: OpenAI has confidentially filed paperwork for an initial public offering, keeping the door open to what could be one of the biggest Wall Street debuts in years. The company says it hasn’t decided when—or even whether—to go public, noting that staying private can make some strategic moves simpler. But the filing matters because it signals readiness, and it comes as investor appetite for AI exposure remains intense. OpenAI’s scale is enormous—ChatGPT is now estimated at roughly 900 million monthly users—yet profitability is still out of reach, largely because running and expanding AI systems requires massive data-center capacity and expensive computing. There’s also a secondary story here: OpenAI is reported to be considering a share sale that would let employees cash out some stock while the company weighs IPO timing—an event that could ripple through tech hubs via hiring, investment, and even housing markets. Iran–Israel ceasefire and Hormuz In the semiconductor world, NVIDIA and SK hynix announced a long-term partnership aimed at next-generation memory and faster chip development—one more sign that the AI boom is now constrained not just by ideas, but by components and supply. In plain terms, modern AI systems are hungry for fast memory and reliable production, and chipmakers are trying to shorten the time it takes to design and ramp manufacturing. The significance isn’t the brand names—it’s the direction: more automation in factories, more coordination across the supply chain, and an arms-race pace to support what companies increasingly call “AI factories.” China’s export surge and surplus Now to security and geopolitics. A major new SIPRI report warns that nuclear-armed states are again treating nuclear weapons as central tools of national power, reversing decades of efforts to reduce their role. SIPRI estimates the world still has over twelve thousand nuclear warheads, with thousands in military stockpiles and a significant number deployed and ready—especially in the U.S. and Russia. The real alarm bell is the trend line: modernization is accelerating across all nuclear-armed states, transparency is shrinking, and crisis-management channels are weaker. This warning lands right after the expiration of the New START treaty earlier this year, which had been one of the last major guardrails limiting U.S. and Russian strategic weapons. SIPRI also flags China’s rapid build-up and renewed European debate about nuclear arrangements—signals that the old arms-control era is giving way to a more uncertain, competitive one. NVIDIA and SK hynix AI memory push In the Middle East, President Donald Trump said a deal to end the Iran–Israel war could be reached within a matter of days, claiming both sides had agreed through him to halt strikes. He also suggested the agreement would include preventing Iran from obtaining nuclear weapons and reopening the Strait of Hormuz. But the immediate reality looks fragile. A ceasefire that’s been in place since April reportedly suffered a recent breakdown after strikes linked to Hezbollah in Beirut, followed by Iranian missile retaliation and then Israeli strikes inside Iran. Even when leaders signal restraint, the region’s interconnected fronts mean a single incident can spiral quickly. Why the Strait of Hormuz keeps coming up is straightforward: it’s a critical route for global oil shipping, and anything that threatens passage can quickly rattle energy markets and broader economic confidence. Glioblastoma fight and new research And finally, China’s economic pulse. New data show exports accelerated sharply in May, with import growth also strong and the trade surplus widening. Analysts say overseas buyers may have rushed orders early—trying to lock in supplies amid uncertainty tied to the Gulf conflict and possible price increases, while demand for AI-related hardware remained strong. Economists caution this may not last: other factory indicators suggest new export orders are already cooling, which could mean the surge was partly a timing effect. Still, it matters because exports remain a preferred engine for China’s growth at a time when domestic demand is uneven—and because a rising surplus adds fuel to international criticism over subsidies and industrial overcapacity. Subscribe to edition specific feeds: - Space news * Apple Podcast English [https://apple.co/4cLLrdt] * Spotify English [https://spoti.fi/4jN8Dui] * RSS English [https://bit.ly/the_automated_daily_space] Spanish [https://theautomateddaily.com/space_es/feed.xml] French [https://theautomateddaily.com/space_fr/feed.xml] - Top news * Apple Podcast English [https://apple.co/3PTvdUF] Spanish [https://apple.co/3ECCMgk] French [https://apple.co/4hmcxbB] * Spotify English [https://spoti.fi/3ZYXAW2] Spanish [https://spoti.fi/414h4JD] French [https://spoti.fi/3Di0jDe] * RSS English [https://bit.ly/the_automated_daily_news] Spanish [https://bit.ly/the_automated_daily_news_es] French [https://bit.ly/the_automated_daily_news_fr] - Tech news * Apple Podcast English [https://apple.co/3RYWbg4] Spanish [https://apple.co/4i0WqRM] French [https://apple.co/4bEAXMm] * Spotify English [https://spoti.fi/3S089pG] Spanish [https://spoti.fi/3EE2Fwv] Spanish [https://spoti.fi/3DlObRE] * RSS English [https://bit.ly/the_automated_daily_tech] Spanish [https://bit.ly/the_automated_daily_tech_es] French [https://bit.ly/the_automated_daily_tech_fr] - Hacker news * Apple Podcast English [https://apple.co/48QWyzj] Spanish [https://apple.co/4ke9jtE] French [https://apple.co/41E1qFd] * Spotify English [https://spoti.fi/45zD1kf] Spanish [https://spoti.fi/4hF8h81] French [https://spoti.fi/3QY26Ak] * RSS English [https://bit.ly/the_automated_daily_hacker_news] Spanish [https://bit.ly/the_automated_daily_hacker_news_es] French [https://bit.ly/the_automated_daily_hacker_news_fr] - AI news * Apple Podcast English [https://apple.co/3M6Tg1o] Spanish [https://apple.co/4315L7Y] French [https://apple.co/3DkZbPb] * Spotify English [https://spoti.fi/3tzOfrz] Spanish [https://spoti.fi/416m40q] French [https://spoti.fi/41HuJGW] * RSS English [https://bit.ly/the_automated_daily_hackernews_ai] Spanish [https://bit.ly/the_automated_daily_hackernews_es_ai] French [https://bit.ly/the_automated_daily_hackernews_fr_ai] Visit our website at https://theautomateddaily.com/ [ https://theautomateddaily.com/] Send feedback to feedback@theautomateddaily.com Youtube [https://www.youtube.com/@TheAutomatedDaily] LinkedIn [https://www.linkedin.com/in/the-automated-daily/] X (Twitter) [https://x.com/automated_daily]

Government stakes in AI firms & US military accelerates AI adoption - News (Jun 8, 2026)

Please support this podcast by checking out our sponsors: - Invest Like the Pros with StockMVP - https://www.stock-mvp.com/?via=ron [https://www.stock-mvp.com/?via=ron] - Discover the Future of AI Audio with ElevenLabs - https://try.elevenlabs.io/tad [https://try.elevenlabs.io/tad] - Prezi: Create AI presentations fast - https://try.prezi.com/automated_daily [https://try.prezi.com/automated_daily] Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily [https://buymeacoffee.com/theautomateddaily] TODAY'S TOPICS: GOVERNMENT STAKES IN AI FIRMS - A RARE POLITICAL CROSSOVER IS EMERGING AS DONALD TRUMP AND BERNIE SANDERS BOTH FLOAT IDEAS FOR THE PUBLIC TO SHARE IN AI PROFITS, INCLUDING TALK OF PUBLIC OWNERSHIP STAKES AND WEALTH FUNDS. KEYWORDS: PUBLIC STAKE, AI COMPANIES, JOBS, NATIONAL SECURITY, WEALTH FUND. US MILITARY ACCELERATES AI ADOPTION - A NEW US NATIONAL SECURITY PRESIDENTIAL MEMORANDUM ORDERS FASTER ADOPTION OF ADVANCED AI ACROSS DEFENSE AGENCIES, WITH NEW LIMITS AROUND CENSORSHIP AND UNLAWFUL DOMESTIC SURVEILLANCE. KEYWORDS: PENTAGON, AI MODELS, AUTONOMOUS WEAPONS, PROCUREMENT, GUARDRAILS. ISRAEL–IRAN STRIKES SHAKE MARKETS - ISRAEL LAUNCHED FRESH AIRSTRIKES ON IRAN, MET BY IRANIAN MISSILE FIRE, REVIVING REGIONAL ESCALATION FEARS AND PUSHING OIL HIGHER WHILE EQUITIES SLIPPED. KEYWORDS: AIRSTRIKES, BALLISTIC MISSILES, BRENT CRUDE, REGIONAL CONFLICT, MARKET VOLATILITY. NUCLEAR ARMS ROLLBACK CONCERNS - SIPRI’S YEARBOOK 2026 WARNS THE LONG DECLINE IN GLOBAL NUCLEAR WARHEADS MAY BE ENDING AS MODERNIZATION ACCELERATES, TRANSPARENCY FALLS, AND NEW START HAS EXPIRED. KEYWORDS: SIPRI, NUCLEAR MODERNIZATION, NEW START, HIGH ALERT, ARMS CONTROL. NEW WEEKLY DIABETES DRUG RESULTS - PHASE 3 DATA SUGGESTS THE EXPERIMENTAL WEEKLY INJECTION RETATRUTIDE SIGNIFICANTLY LOWERS HBA1C AND DRIVES NOTABLE WEIGHT LOSS IN ADULTS WITH TYPE 2 DIABETES, THOUGH LONGER-TERM COMPARISONS ARE STILL NEEDED. KEYWORDS: RETATRUTIDE, HBA1C, WEIGHT LOSS, TRIAL RESULTS, SIDE EFFECTS. TWICE-YEARLY HIV PREVENTION ROLLOUT - GAUTENG IS STARTING A ROLLOUT OF LENACAPAVIR, A TWICE-YEARLY HIV PREVENTION INJECTION AIMED AT PEOPLE AT HIGH RISK, SUPPORTING SOUTH AFRICA’S 2030 GOALS. KEYWORDS: LENACAPAVIR, HIV PREVENTION, GAUTENG, LONG-ACTING INJECTION, PUBLIC HEALTH. UK PUSH FOR CHILD SAFETY CONTROLS - UK PRIME MINISTER KEIR STARMER IS PRESSURING TECH COMPANIES TO ADD DEVICE-LEVEL TOOLS TO CURB NUDE IMAGE SHARING BY CHILDREN, WITH LEGISLATION THREATENED IF FIRMS DON’T MOVE QUICKLY. KEYWORDS: CHILD SAFETY, DEVICE-LEVEL CONTROLS, SEXTORTION, AGE CHECKS, REGULATION. CHIP MEMORY SUPPLY FOR AI - NVIDIA AND SK HYNIX ARE TEAMING UP LONG-TERM TO SECURE NEXT-GENERATION MEMORY FOR AI SYSTEMS, REFLECTING HOW HARDWARE SUPPLY CONSTRAINTS ARE SHAPING THE PACE OF AI BUILDOUTS. KEYWORDS: AI INFRASTRUCTURE, MEMORY BOTTLENECK, SEMICONDUCTOR SUPPLY, PARTNERSHIP, CAPACITY. Episode Transcript Government stakes in AI firms Let’s start with artificial intelligence—because the conversation is shifting from “who builds it” to “who benefits from it.” In the US, officials and politicians are increasingly debating whether the public should hold an ownership stake in major AI companies. The argument is straightforward: if AI is going to reshape jobs, productivity, and national security, the upside shouldn’t flow only to private shareholders. OpenAI CEO Sam Altman has reportedly discussed the concept with Senator Bernie Sanders, whose camp has floated a major public stake to fund a public wealth fund—though support for the exact number is far from settled. What’s notable is that President Donald Trump has also talked about Americans becoming “partners” in the AI boom, and is expected to convene top AI leaders at the White House. Abroad, similar instincts are showing up in different forms—like Europe pushing to reduce dependence on US cloud giants for sensitive government work, and the UK setting up a sovereign AI investment fund. No deal is close. But the fact that “public ownership” is now part of the mainstream AI debate signals a turning point: governments are preparing to treat AI less like a typical tech sector—and more like critical infrastructure. US military accelerates AI adoption At the same time, the US is moving to speed AI adoption inside the military. President Trump has signed a National Security Presidential Memorandum directing defense agencies to accelerate the use of advanced AI across missions, and to pull in leading models from multiple vendors rather than relying on a single provider. There are also two political signals baked into the order. One: the Pentagon is being told to update its approach to autonomous weapon systems—an area that’s been debated for years, but is now being pushed toward clearer rules. Two: the memo includes boundaries meant to address public concerns, including language against building defense AI designed to censor speech, embed ideological bias, or enable unlawful surveillance of Americans. Another line stands out for industry: it bars companies from disabling or materially altering AI systems used by US warfighters without government approval. In plain English, once a system is in the field, Washington wants to ensure it can’t be remotely “switched off” by a vendor decision. Israel–Iran strikes shake markets Now to the Middle East, where a fragile pause has been shaken. Israel carried out new airstrikes on Iran—described as the first direct exchange since an April ceasefire that paused a US–Israel war with Iran. Iranian state media reported explosions in multiple cities, including Tehran and Isfahan. Iran then responded by firing around ten ballistic missiles toward northern Israel, after Israel also bombed a target in southern Beirut. President Trump publicly urged both sides to stop shooting, a comment that also highlights the tension between Washington’s stated posture and Israel’s on-the-ground decisions. The ripple effects were immediate across the region: Saudi Arabia reportedly sounded missile-alert sirens near an airbase that hosts US forces, and Israel said it worked to intercept a missile launched from Yemen, where the Houthis have been involved in the broader conflict. Markets reacted fast, too. Oil jumped, with Brent crude rising by several dollars to the mid‑90s per barrel range, and Asian stocks slid. The takeaway is familiar but important: even a limited exchange can quickly raise global economic anxiety, because energy prices and shipping risk can move on headlines alone. Nuclear arms rollback concerns Staying with security—one of the most sobering reads today comes from SIPRI’s Yearbook 2026. The Stockholm International Peace Research Institute warns that nuclear-armed states are increasingly treating nuclear weapons as instruments of national power again—reversing decades of efforts to reduce their role. SIPRI estimates the world had a little over twelve thousand nuclear warheads as of January 2026, with thousands in military stockpiles and roughly four thousand deployed. A significant share of deployed warheads remain on high operational alert, mostly in Russia and the United States. The big shift is trendline and trust. SIPRI expects the long-running decline in total warhead numbers to end, as dismantlement slows and new deployments accelerate. That warning lands as New START—the last major US–Russia nuclear arms control agreement—expired in February 2026. Add reduced transparency, weaker crisis-management channels, and rising geopolitical tension, and you get a higher risk of miscalculation. The report also points to China as the fastest-growing arsenal, while noting the US and Russia still hold the vast majority of stockpiled warheads—and both are modernizing under intense strategic competition. In Europe, SIPRI flags renewed debate about a bigger nuclear role in security planning, including interest in broader nuclear-sharing arrangements, alongside claims of Russian nuclear deployments in Belarus. And politically, the non-proliferation system looks shakier after the 2026 NPT Review Conference again failed to produce an outcome document—raising questions about how much cooperation remains in the tank. New weekly diabetes drug results On health news, there’s a potentially significant development for type 2 diabetes. Phase 3 trial results suggest an experimental weekly injection called retatrutide can both lower blood sugar and reduce body weight—two outcomes that are often linked, but not always easy to achieve together. In a forty-week study of adults not already on diabetes medication, average long-term blood sugar, measured by HbA1c, fell substantially more with retatrutide than with placebo. Participants also saw sizable average weight loss, alongside improvements in markers like cholesterol and blood pressure. Experts describe the results as encouraging—possibly life-changing for some patients—but there are important caveats. We still need longer-term data, and there wasn’t a direct head-to-head comparison here against some of today’s leading drugs. And like other medicines in this space, side effects were mainly gastrointestinal, with a small number of serious adverse events reported across the study groups. The story to watch next is how it performs over time, in real-world care, and against established options. Twice-yearly HIV prevention rollout Also in public health, South Africa is expanding prevention tools against HIV. Gauteng’s Department of Health says it will begin rolling out lenacapavir on Monday as a long-acting prevention injection. The key practical difference: it’s given only twice a year, aimed at HIV-negative people at high risk of infection. The first phase is planned across more than a hundred facilities, with tens of thousands of people expected to receive the injection by early next year. Officials say supplies will be delivered regularly to avoid interruptions. Why it’s interesting is not just the medicine, but the strategy: offering choices. Long-acting prevention can help people who struggle with daily pills, or who face barriers like stigma, unstable schedules, or limited clinic access. It’s part of a broader push toward ending AIDS as a public health threat by 2030—and it puts a spotlight on whether health systems can scale prevention in a way that’s consistent and equitable. UK push for child safety controls In the UK, the government is turning up the pressure on tech companies over child safety. Prime Minister Keir Starmer has given major firms three months to introduce device-level controls meant to stop children from sending or receiving nude images. If companies don’t comply, the government is warning it will legislate. The concept is a shift in responsibility: not just moderating content after it appears on a platform, but building safeguards into the devices themselves—so the camera and operating system can detect and block explicit imagery in the moment. Politics around the plan are already heated. Critics from across the spectrum argue the government is either moving too slowly or aiming at the wrong target, and ministers are also weighing an under‑16 social media ban while gathering evidence on screen-time guidance and device use in schools. The broader context is grim: online exploitation is evolving, including AI-generated child abuse material and sextortion schemes. The policy question is how far governments should go in mandating “safety by default,” and how to do it without creating new privacy or enforcement problems. Chip memory supply for AI Finally, in tech industry news with real-world consequences for AI’s pace: NVIDIA and SK hynix have announced a long-term partnership to co-develop next-generation memory aimed at large-scale AI systems. This matters because the bottlenecks in AI aren’t only about chips with flashy headlines—memory supply and performance can be the limiting factor for building and running powerful systems at scale. Securing reliable access, and shortening development timelines, can influence everything from data center expansion to the cost of deploying AI in business and government. The two companies also signaled they want to use AI-driven simulation and “digital twin” techniques to streamline chip development and manufacturing. Put simply: using sophisticated modeling to design faster, waste less, and get new hardware into production sooner. Subscribe to edition specific feeds: - Space news * Apple Podcast English [https://apple.co/4cLLrdt] * Spotify English [https://spoti.fi/4jN8Dui] * RSS English [https://bit.ly/the_automated_daily_space] Spanish [https://theautomateddaily.com/space_es/feed.xml] French [https://theautomateddaily.com/space_fr/feed.xml] - Top news * Apple Podcast English [https://apple.co/3PTvdUF] Spanish [https://apple.co/3ECCMgk] French [https://apple.co/4hmcxbB] * Spotify English [https://spoti.fi/3ZYXAW2] Spanish [https://spoti.fi/414h4JD] French [https://spoti.fi/3Di0jDe] * RSS English [https://bit.ly/the_automated_daily_news] Spanish [https://bit.ly/the_automated_daily_news_es] French [https://bit.ly/the_automated_daily_news_fr] - Tech news * Apple Podcast English [https://apple.co/3RYWbg4] Spanish [https://apple.co/4i0WqRM] French [https://apple.co/4bEAXMm] * Spotify English [https://spoti.fi/3S089pG] Spanish [https://spoti.fi/3EE2Fwv] Spanish [https://spoti.fi/3DlObRE] * RSS English [https://bit.ly/the_automated_daily_tech] Spanish [https://bit.ly/the_automated_daily_tech_es] French [https://bit.ly/the_automated_daily_tech_fr] - Hacker news * Apple Podcast English [https://apple.co/48QWyzj] Spanish [https://apple.co/4ke9jtE] French [https://apple.co/41E1qFd] * Spotify English [https://spoti.fi/45zD1kf] Spanish [https://spoti.fi/4hF8h81] French [https://spoti.fi/3QY26Ak] * RSS English [https://bit.ly/the_automated_daily_hacker_news] Spanish [https://bit.ly/the_automated_daily_hacker_news_es] French [https://bit.ly/the_automated_daily_hacker_news_fr] - AI news * Apple Podcast English [https://apple.co/3M6Tg1o] Spanish [https://apple.co/4315L7Y] French [https://apple.co/3DkZbPb] * Spotify English [https://spoti.fi/3tzOfrz] Spanish [https://spoti.fi/416m40q] French [https://spoti.fi/41HuJGW] * RSS English [https://bit.ly/the_automated_daily_hackernews_ai] Spanish [https://bit.ly/the_automated_daily_hackernews_es_ai] French [https://bit.ly/the_automated_daily_hackernews_fr_ai] Visit our website at https://theautomateddaily.com/ [ https://theautomateddaily.com/] Send feedback to feedback@theautomateddaily.com Youtube [https://www.youtube.com/@TheAutomatedDaily] LinkedIn [https://www.linkedin.com/in/the-automated-daily/] X (Twitter) [https://x.com/automated_daily]

Base editing in human embryos & AI-designed universal coronavirus vaccine - News (Jun 7, 2026)

Please support this podcast by checking out our sponsors: - Invest Like the Pros with StockMVP - https://www.stock-mvp.com/?via=ron [https://www.stock-mvp.com/?via=ron] - Prezi: Create AI presentations fast - https://try.prezi.com/automated_daily [https://try.prezi.com/automated_daily] - Effortless AI design for presentations, websites, and more with Gamma - https://try.gamma.app/tad [https://try.gamma.app/tad] Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily [https://buymeacoffee.com/theautomateddaily] TODAY'S TOPICS: BASE EDITING IN HUMAN EMBRYOS - A COLUMBIA UNIVERSITY TEAM REPORTED BASE EDITING IN EARLY HUMAN EMBRYOS IN A BIORXIV PREPRINT, REVIVING SAFETY AND ETHICS DEBATES AFTER THE CRISPR-BABY SCANDAL. KEYWORDS: BASE EDITING, EMBRYOS, MOSAICISM, ETHICS, CRISPR. AI-DESIGNED UNIVERSAL CORONAVIRUS VACCINE - CAMBRIDGE RESEARCHERS SAY AN AI-DESIGNED “UNIVERSAL SARBECOVIRUS” VACCINE LOOKED SAFE IN A SMALL PHASE 1 TRIAL, AIMING FOR BROAD PROTECTION ACROSS SARS-LIKE VIRUSES. KEYWORDS: AI VACCINE DESIGN, SARBECOVIRUS, PHASE 1, VARIANTS, PREPAREDNESS. NEW WEIGHT-LOSS SHOT FOR DIABETES - PHASE 3 RESULTS SUGGEST RETATRUTIDE, A WEEKLY TRIPLE-ACTION INJECTION, LOWERED HBA1C AND WEIGHT IN TYPE 2 DIABETES, THOUGH LONGER-TERM COMPARISONS ARE STILL NEEDED. KEYWORDS: RETATRUTIDE, TYPE 2 DIABETES, HBA1C, WEIGHT LOSS, GLP-1. TWICE-YEARLY HIV PREVENTION INJECTION - SOUTH AFRICA’S GAUTENG PROVINCE IS ROLLING OUT LENACAPAVIR, A TWICE-YEARLY HIV PREVENTION SHOT, FOCUSING ON HIGH-RISK GROUPS TO SUPPORT THE 2030 AIDS GOALS. KEYWORDS: LENACAPAVIR, PREP, LONG-ACTING INJECTION, GAUTENG, HIV PREVENTION. ROBOTS VS REALITY IN CHINA - CHINA’S HUMANOID ROBOTS ARE GETTING FLASHIER AND DRAWING ORDERS, BUT ANALYSTS SAY REAL-WORLD USEFULNESS STILL LAGS AND COMMERCIALIZATION REMAINS LIMITED. KEYWORDS: HUMANOID ROBOTS, CHINA, ROBOTICS DEMAND, LOGISTICS, BUBBLE RISK. US MILITARY AI ACCELERATION MEMO - PRESIDENT TRUMP SIGNED A NATIONAL SECURITY MEMO PUSHING FASTER ADOPTION OF ADVANCED AI ACROSS US DEFENSE AGENCIES, INCLUDING NEW ATTENTION TO AUTONOMOUS WEAPONS POLICY. KEYWORDS: PENTAGON AI, NATIONAL SECURITY MEMORANDUM, AUTONOMOUS WEAPONS, VENDORS, GOVERNANCE. PUBLIC STAKE IDEA FOR AI FIRMS - THE WHITE HOUSE HAS DISCUSSED WAYS FOR THE PUBLIC TO SHARE IN AI-COMPANY GAINS, INCLUDING A REPORTED CONCEPT OF AN EQUITY STAKE IN OPENAI TIED TO A PUBLIC WEALTH FUND. KEYWORDS: OPENAI STAKE, PUBLIC WEALTH FUND, AI POLICY, GOVERNMENT OWNERSHIP, EQUITY. AUSTRALIA’S AI DATA-CENTER POWER CRUNCH - AUSTRALIA’S DATA-CENTER BOOM IS POWERING CONSTRUCTION GROWTH BUT RAISING CONCERNS ABOUT ELECTRICITY DEMAND, PRICE PRESSURE, AND HOW MUCH LONG-TERM VALUE STAYS ONSHORE. KEYWORDS: AUSTRALIA DATA CENTERS, AI BOOM, AEMO, POWER DEMAND, WHOLESALE PRICES. US-IRAN TALKS ON ENDING WAR - TRUMP SAYS THE US AND IRAN ARE CLOSE TO AN AGREEMENT TO END A THREE-MONTH CONFLICT, BUT URANIUM REMOVAL AND VERIFICATION DETAILS REMAIN THE CRUCIAL STICKING POINTS. KEYWORDS: US-IRAN DEAL, ENRICHED URANIUM, VERIFICATION, TROOPS, CEASEFIRE TALKS. NASA’S QUIET-SUPERSONIC X-59 MILESTONE - NASA’S X-59 ACHIEVED ITS FIRST SUPERSONIC FLIGHT, ADVANCING A PROGRAM DESIGNED TO REDUCE SONIC BOOMS AND POTENTIALLY REOPEN OVERLAND SUPERSONIC TRAVEL. KEYWORDS: NASA X-59, QUESST, SUPERSONIC, SONIC BOOM, REGULATIONS. Episode Transcript Base editing in human embryos We’ll start with the headline that’s raising eyebrows in both science and ethics circles. A research team led by Dieter Egli at Columbia University has posted a preprint describing what appears to be the first use of “base editing” in early-stage human embryos. Unlike older approaches that cut DNA, base editing aims for more precise, single-letter changes—on paper, a safer direction. But the results still show major hurdles: edits often appeared in some cells but not others, and at higher doses the process could even stop embryos from dividing. The bigger story here is what this unlocks—and what it tempts. Supporters see a path toward mimicking naturally protective mutations tied to lower heart-disease risk or reduced severity in blood disorders like sickle cell disease. Critics warn it could make “embryo improvement” feel more reachable than it should, especially given how widely IVF and genetic testing are already available. For now, the message from the data is clear: the science is advancing, but it’s far from clinic-ready. AI-designed universal coronavirus vaccine Staying with health—and shifting from controversy to preparedness—researchers at the University of Cambridge and their spin-out, DIOSynVax, say they’ve completed an early human trial of a vaccine antigen designed entirely with computer simulations and machine learning. In a small Phase 1 study of healthy volunteers, the team reports no significant side effects. The ambition is the striking part: instead of building a vaccine around one known virus, they designed an antigen meant to represent shared features across the broader “sarbecovirus” family—the group that includes SARS-CoV-1 and SARS-CoV-2. If later trials show strong protection, it could mean fewer frantic updates every time a new variant appears, and faster vaccine design when a new relative of COVID shows up. New weight-loss shot for diabetes Another medical update with major real-world stakes: Phase 3 trial results suggest the experimental weekly injection retatrutide helped adults with type 2 diabetes significantly lower blood sugar and lose substantial weight over 40 weeks. Participants who weren’t already on diabetes medication saw meaningfully larger drops in HbA1c than placebo, and also lost far more body weight, alongside improvements in cholesterol and blood pressure. Researchers describe retatrutide as a “triple-action” drug, aiming to tackle appetite, glucose control, and energy use at the same time. Side effects were mostly in the familiar category for this class of drugs—mainly gastrointestinal—and experts are encouraged, while also pointing out what’s still missing: longer-term data and direct comparisons with established treatments like semaglutide or tirzepatide. Twice-yearly HIV prevention injection From treatment to prevention: South Africa’s Gauteng Department of Health is beginning a rollout of lenacapavir as a long-acting HIV prevention injection. It’s given twice a year and is aimed at HIV-negative people at higher risk of infection. The plan is to start across more than a hundred health facilities in the province, with a goal of reaching tens of thousands of people over the coming months. Public health officials are prioritizing groups that have often been underserved by prevention tools—especially adolescent girls and young women, sex workers, and others who face elevated risk. The significance is straightforward: adherence has long been one of the biggest barriers for HIV prevention, and a twice-yearly option could make staying protected much more realistic for many people. Robots vs reality in China Now to technology and the economy—and a reality check on humanoid robots. In China, robot makers are showing off increasingly agile humanoids, with companies claiming thousands of orders from governments and businesses. But analysts and investors are warning that demand still isn’t matching the scale of manufacturing ambition. A lot of these machines look impressive in controlled demos, yet struggle with messy, unpredictable environments—the places where a “general-purpose helper” would actually have to work. The near-term opportunity appears more practical: industrial sites and logistics, like warehouses, power plants, and data centers, where tasks are more structured and where a robot’s limits can be managed. The broader race is also taking shape geopolitically: the US is widely seen as stronger on advanced AI systems, while China’s edge is hardware supply chains, data, and mass production. Chinese regulators, notably, have even warned about bubble dynamics—big expectations, but limited real commercialization so far. US military AI acceleration memo On the US policy front, President Trump has signed a National Security Presidential Memorandum pushing faster adoption of advanced AI across defense agencies. The memo calls for rapid onboarding of top AI models from multiple vendors and for adapting commercial and open-source tools for military missions. It also signals more formal attention to autonomous weapons policy, directing the Defense Department to update guidance on how those systems are governed. One notable clause says companies shouldn’t be able to disable or modify AI used by US warfighters without government approval—an attempt to prevent critical tools from being turned off in a crisis. The memo also includes language aiming to limit certain domestic risks, saying defense agencies shouldn’t create or release AI designed to censor free speech, embed ideological bias, or enable unlawful surveillance of Americans. The big picture: Washington is trying to move quickly on military AI while also drawing some red lines—though how those lines hold up in practice is the real test. Public stake idea for AI firms And there’s another AI-related idea circulating that could reshape how the public relates to the industry. Trump says he’s been talking with AI companies about arrangements that would let “the American people” benefit directly from AI’s success. Reporting suggests discussions have included the federal government taking an equity stake in OpenAI, potentially routing proceeds into a proposed “Public Wealth Fund.” Supporters frame it as the public getting a stake in a transformational technology. Critics see risks: deeper government-corporate entanglement, and the possibility that ownership becomes a backdoor route to bailouts or political influence. It’s also notable that a similar concept is appearing from the political left, with proposals for AI companies to pay a tax in shares. Regardless of ideology, the underlying question is the same: if AI creates enormous private value, should the public have a built-in claim on part of it? Australia’s AI data-center power crunch Australia offers a different angle on the AI boom: the infrastructure behind it. The country is seeing a surge in data-center investment, including a proposed multi-billion-dollar complex in Sydney’s outer west. In the near term, it’s a genuine economic boost—big construction activity, big capital flows. But analysts warn the longer-term gains may be thinner than they look. Much of the highest-value equipment is imported, data centers run with relatively small staffing footprints, and there are mounting concerns about electricity demand. Australia’s energy market operator forecasts data-center power use rising fast, and climate analysts warn that if new renewable generation and storage don’t keep pace, wholesale power prices could rise materially over the next decade. Add in longstanding debates about how much tax revenue big tech contributes locally, and the question becomes: who really profits, and who pays for the grid upgrades? US-Iran talks on ending war To geopolitics now, where President Trump says the US and Iran are “very close” to an agreement meant to end a three-month conflict. Trump claims Iran has accepted it will not possess nuclear weapons, and he says remaining gaps are now down to wording—specifically, language that would bar Iran not only from developing a nuclear weapon, but from acquiring one by any means. He also emphasized the handling of Iran’s highly enriched uranium stockpile, arguing it should be removed and destroyed, with the US prepared to help do that either on-site or elsewhere in cooperation with Iran. The significance here is the potential for a diplomatic off-ramp from a volatile conflict. But the durability of any deal will hinge on the hard parts: verification, monitoring, and exactly what happens to nuclear material. Those details are often where agreements either become enforceable—or unravel. NASA’s quiet-supersonic X-59 milestone Finally, a milestone in the sky: NASA’s experimental X-59 aircraft has completed its first supersonic flight, breaking the sound barrier on June 5 as part of the agency’s Quesst mission. The point isn’t just speed. It’s noise. Supersonic passenger travel over land has been heavily restricted for decades largely because of the disruptive sonic boom. The X-59 is designed to soften that boom into something closer to a quiet thump, collecting the data NASA hopes could one day support new rules for overland supersonic flight. Next comes a careful expansion of the flight envelope—pushing faster and higher—before NASA can start answering the big question: can supersonic travel return without rattling the ground below? Subscribe to edition specific feeds: - Space news * Apple Podcast English [https://apple.co/4cLLrdt] * Spotify English [https://spoti.fi/4jN8Dui] * RSS English [https://bit.ly/the_automated_daily_space] Spanish [https://theautomateddaily.com/space_es/feed.xml] French [https://theautomateddaily.com/space_fr/feed.xml] - Top news * Apple Podcast English [https://apple.co/3PTvdUF] Spanish [https://apple.co/3ECCMgk] French [https://apple.co/4hmcxbB] * Spotify English [https://spoti.fi/3ZYXAW2] Spanish [https://spoti.fi/414h4JD] French [https://spoti.fi/3Di0jDe] * RSS English [https://bit.ly/the_automated_daily_news] Spanish [https://bit.ly/the_automated_daily_news_es] French [https://bit.ly/the_automated_daily_news_fr] - Tech news * Apple Podcast English [https://apple.co/3RYWbg4] Spanish [https://apple.co/4i0WqRM] French [https://apple.co/4bEAXMm] * Spotify English [https://spoti.fi/3S089pG] Spanish [https://spoti.fi/3EE2Fwv] Spanish [https://spoti.fi/3DlObRE] * RSS English [https://bit.ly/the_automated_daily_tech] Spanish [https://bit.ly/the_automated_daily_tech_es] French [https://bit.ly/the_automated_daily_tech_fr] - Hacker news * Apple Podcast English [https://apple.co/48QWyzj] Spanish [https://apple.co/4ke9jtE] French [https://apple.co/41E1qFd] * Spotify English [https://spoti.fi/45zD1kf] Spanish [https://spoti.fi/4hF8h81] French [https://spoti.fi/3QY26Ak] * RSS English [https://bit.ly/the_automated_daily_hacker_news] Spanish [https://bit.ly/the_automated_daily_hacker_news_es] French [https://bit.ly/the_automated_daily_hacker_news_fr] - AI news * Apple Podcast English [https://apple.co/3M6Tg1o] Spanish [https://apple.co/4315L7Y] French [https://apple.co/3DkZbPb] * Spotify English [https://spoti.fi/3tzOfrz] Spanish [https://spoti.fi/416m40q] French [https://spoti.fi/41HuJGW] * RSS English [https://bit.ly/the_automated_daily_hackernews_ai] Spanish [https://bit.ly/the_automated_daily_hackernews_es_ai] French [https://bit.ly/the_automated_daily_hackernews_fr_ai] Visit our website at https://theautomateddaily.com/ [ https://theautomateddaily.com/] Send feedback to feedback@theautomateddaily.com Youtube [https://www.youtube.com/@TheAutomatedDaily] LinkedIn [https://www.linkedin.com/in/the-automated-daily/] X (Twitter) [https://x.com/automated_daily]

Embryo base editing milestone & AI-designed universal coronavirus vaccine - News (Jun 6, 2026)

Please support this podcast by checking out our sponsors: - Discover the Future of AI Audio with ElevenLabs - https://try.elevenlabs.io/tad [https://try.elevenlabs.io/tad] - Consensus: AI for Research. Get a free month - https://get.consensus.app/automated_daily [https://get.consensus.app/automated_daily] - KrispCall: Agentic Cloud Telephony - https://try.krispcall.com/tad [https://try.krispcall.com/tad] Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily [https://buymeacoffee.com/theautomateddaily] TODAY'S TOPICS: EMBRYO BASE EDITING MILESTONE - SCIENTISTS REPORTED THE FIRST USE OF BASE EDITING IN EARLY-STAGE HUMAN EMBRYOS, A MORE PRECISE CRISPR-STYLE METHOD, RAISING FRESH SAFETY AND ETHICS CONCERNS AROUND MOSAICISM AND ENHANCEMENT. AI-DESIGNED UNIVERSAL CORONAVIRUS VACCINE - A CAMBRIDGE TEAM SAYS AN AI-DESIGNED CORONAVIRUS “SUPER-ANTIGEN” HAS BEEN TESTED IN HUMANS, AIMING FOR BROAD PROTECTION ACROSS CORONAVIRUSES AND FUTURE SPILLOVERS—EARLY RESULTS WERE MODEST BUT PROMISING. LONG-ACTING HIV PREVENTION ROLLOUT - SOUTH AFRICA BEGAN ROLLING OUT LENACAPAVIR, A TWICE-YEARLY PREP INJECTION THAT COULD BOOST HIV PREVENTION BY SOLVING DAILY-PILL ADHERENCE ISSUES, BUT ACCESS IS CONSTRAINED BY FUNDING CUTS AND LIMITED SUPPLY. NEW KRAS PANCREATIC CANCER DRUG - PHASE 3 RESULTS FOR DARAXONRASIB SHOWED MARKEDLY LONGER SURVIVAL IN KRAS-DRIVEN METASTATIC PANCREATIC CANCER, POTENTIALLY RESHAPING TREATMENT FOR A HISTORICALLY HARD-TO-TREAT DISEASE IF REGULATORS APPROVE IT. CHINA’S HUMANOID ROBOT REALITY CHECK - CHINA’S HUMANOID ROBOT MAKERS CLAIM THOUSANDS OF ORDERS AND SHOW OFF AGILE MACHINES, BUT ANALYSTS WARN REAL-WORLD USEFULNESS STILL LAGS BEHIND PRODUCTION AMBITIONS DUE TO COST, FRAGILITY, AND MESSY ENVIRONMENTS. CANADA’S AI SOVEREIGNTY STRATEGY - CANADA UNVEILED A DECADE-LONG AI STRATEGY FOCUSED ON ADOPTION, AI LITERACY, AND “AI SOVEREIGNTY,” INCLUDING PLANS FOR DOMESTIC COMPUTE CAPACITY AND SUPPORT TO KEEP TALENT AND COMPANIES AT HOME. SELF-IMPROVING AI AND RESEARCH RACE - FROM ANTHROPIC’S AI-WRITTEN CODE TO JAPAN-U.S. AUTONOMOUS LABS, THE COMPETITIVE EDGE IS SHIFTING TOWARD CONTROLLED FEEDBACK LOOPS WHERE AI HELPS IMPROVE PRODUCTS AND SPEED UP SCIENCE—WITHOUT FULLY AUTONOMOUS SELF-UPGRADES. Episode Transcript Embryo base editing milestone We’ll start with that embryo-editing headline. Researchers led by Dieter Egli at Columbia University reported what they describe as the first use of “base editing” to change single DNA letters in early-stage human embryos. This was shared as a bioRxiv preprint, meaning it hasn’t been peer reviewed yet. Supporters say this matters because base editing can avoid the kind of double-strand DNA cuts that made earlier embryo experiments look especially risky. But the study also underlines how far this is from clinical reality: many embryos ended up “mosaic,” with edits in some cells but not others, and higher doses of the editor delivery appeared to stall cell division. The bigger reason this is back in the spotlight is ethical, not technical. After the 2018 CRISPR-baby scandal, researchers and regulators have tried to draw bright lines. Critics worry that relatively accessible IVF and genetic testing could tempt reckless attempts at so-called improvement—long before safety is there. Others argue that for many inherited diseases, existing embryo screening can already reduce risk without editing, which raises an uncomfortable question: does the first real demand end up being enhancement rather than therapy? AI-designed universal coronavirus vaccine Staying with health—this time, with a more hopeful story—South Africa has begun rolling out lenacapavir, a long-acting HIV prevention injection given just twice a year. The significance is simple: daily PrEP pills work well when taken consistently, but adherence is often the weak link, especially among adolescents and young women—groups that account for a large share of new infections. A twice-yearly shot could remove a huge practical barrier. The catch is access. The program is launching in hundreds of facilities in high-burden districts, but experts say the scale is limited by reduced prevention capacity after U.S. PEPFAR funding cuts, plus constrained supply and the lack of low-cost generics today. The Global Fund is financing enough doses for hundreds of thousands of people over two years—valuable, but still far from the kind of coverage that would rapidly bend national infection curves. The stakes are big: models suggest that with sustained, large-scale rollout over time, South Africa could push AIDS out of the “major public health problem” category. But that hinges on money, supply, and follow-through. Long-acting HIV prevention rollout Now to cancer treatment, where a single trial result can change the standard conversation. Researchers reported Phase 3 results for daraxonrasib, a targeted therapy for KRAS-driven metastatic pancreatic cancer. KRAS mutations are behind the vast majority of pancreatic tumors, and for years KRAS was treated like a near-impossible drug target. In this 500-patient trial for previously treated metastatic disease, overall survival increased from about 6.7 months with standard chemotherapy to 13.2 months with daraxonrasib. That’s a striking jump in a cancer known for grim outcomes. Side effects were common—things like rash, mouth sores, and gastrointestinal problems—but fewer people stopped treatment than with chemotherapy, and patients reported better quality of life. The company plans to seek regulatory approval, and if that moves quickly, oncologists could soon have a new cornerstone drug—and a new platform for combination therapies aimed at delaying resistance. New KRAS pancreatic cancer drug Let’s pivot to AI meeting biology in a different way. Researchers at the University of Cambridge say they’ve tested in humans a vaccine concept whose key antigen was designed entirely by artificial intelligence. Instead of chasing the latest variant, the AI reportedly sifted genetic sequences from many coronaviruses gathered through surveillance and designed a kind of broad “super-antigen,” aiming to train immunity across the coronavirus family—including possible future spillovers from animals. In a small first trial of 39 people, the main focus was safety, and the immune response was described as modest. That’s not a victory lap—but it is a proof-of-concept moment: the idea that you might pre-build vaccine candidates for viral families before the next outbreak. A larger study is planned to better measure effectiveness, and the same approach is being explored for other threats, including flu and H5N1. China’s humanoid robot reality check From vaccines to the physics lab: researchers at Chalmers University of Technology say they’ve cut the time needed to design advanced optical components by building the laws of physics into a neural network. In plain terms, instead of forcing an AI to learn electromagnetism the hard way—by chewing through huge volumes of simulation data—they gave the model a built-in understanding of key physical constraints. The result: far less training data needed, fewer obvious errors, and a dramatic reduction in the time it takes to evaluate new designs. Why it matters is what it enables: thinner, lighter optical systems, and potentially better photonic structures for future technologies—where traditional simulation can be painfully slow and expensive. It’s a reminder that the most useful “AI breakthroughs” aren’t always about bigger models; sometimes they’re about smarter rules. Canada’s AI sovereignty strategy Now to robots—specifically China’s push for humanoids. Chinese manufacturers are showing increasingly agile humanoid machines that can pull stunts and handle basic service tasks, and some companies claim they already have thousands of orders from governments and businesses. But analysts and investors are throwing cold water on the hype: demand may still be trailing factory ambitions because many humanoids look more impressive on a demo stage than they do in messy, unpredictable real-world settings. Fragile parts, high costs, and the need for structured environments are still big barriers. The geopolitical angle is also clear. The U.S. and China dominate the field, with the U.S. often viewed as stronger in the AI “brains,” while China leads in hardware supply chains, data collection at scale, and mass production capacity—plus strong policy support. In the near term, the most realistic growth is expected in controlled industrial settings like warehouses, power plants, and data centers, long before most people have a reliable household helper. Self-improving AI and research race Let’s talk policy and power—AI power, specifically. Canada has unveiled a national AI strategy for the next decade, framed by Prime Minister Mark Carney as an inevitability Canada needs to shape rather than fear. The plan includes major spending aimed at AI literacy and adoption across business and government, and it puts a name on a growing theme: “AI sovereignty.” The goal is to reduce reliance on foreign providers by expanding domestic computing capacity, including a secure public supercomputer and support for large-scale data centers. Canada also wants to keep talent from leaving—through research funding, university chairs, and faster immigration pathways for skilled workers—plus funding to invest in Canadian AI companies. One point drawing criticism: the strategy talks a lot about trust and safety concerns, but offers fewer concrete details on new safety rules than some Canadians expected. Story 8 Finally, the AI industry itself is evolving in a way that’s less sci-fi—and more operational. Companies are building feedback loops where AI helps create the next iteration of software and even AI itself. Anthropic says its models now write the majority of code merged into its codebase, shifting human engineers toward oversight, review, and deciding what “good” looks like. Microsoft is pushing a controlled version of continuous learning in workplaces—updating models based on real organizational workflows, but inside auditable guardrails. And Google DeepMind has been blunt that fully autonomous self-improvement still hits hard limits, especially when it comes to verifying progress in the real world. Layer that onto the broader economy: Forbes reports global billionaire wealth hit a new record, driven in large part by the AI boom—chips, data centers, cloud spending, and the companies that sit in the middle of that supply chain. The headline isn’t just that AI is making money; it’s who it’s making money for—founders and early investors—widening the inequality debate that policymakers are now forced to confront. Subscribe to edition specific feeds: - Space news * Apple Podcast English [https://apple.co/4cLLrdt] * Spotify English [https://spoti.fi/4jN8Dui] * RSS English [https://bit.ly/the_automated_daily_space] Spanish [https://theautomateddaily.com/space_es/feed.xml] French [https://theautomateddaily.com/space_fr/feed.xml] - Top news * Apple Podcast English [https://apple.co/3PTvdUF] Spanish [https://apple.co/3ECCMgk] French [https://apple.co/4hmcxbB] * Spotify English [https://spoti.fi/3ZYXAW2] Spanish [https://spoti.fi/414h4JD] French [https://spoti.fi/3Di0jDe] * RSS English [https://bit.ly/the_automated_daily_news] Spanish [https://bit.ly/the_automated_daily_news_es] French [https://bit.ly/the_automated_daily_news_fr] - Tech news * Apple Podcast English [https://apple.co/3RYWbg4] Spanish [https://apple.co/4i0WqRM] French [https://apple.co/4bEAXMm] * Spotify English [https://spoti.fi/3S089pG] Spanish [https://spoti.fi/3EE2Fwv] Spanish [https://spoti.fi/3DlObRE] * RSS English [https://bit.ly/the_automated_daily_tech] Spanish [https://bit.ly/the_automated_daily_tech_es] French [https://bit.ly/the_automated_daily_tech_fr] - Hacker news * Apple Podcast English [https://apple.co/48QWyzj] Spanish [https://apple.co/4ke9jtE] French [https://apple.co/41E1qFd] * Spotify English [https://spoti.fi/45zD1kf] Spanish [https://spoti.fi/4hF8h81] French [https://spoti.fi/3QY26Ak] * RSS English [https://bit.ly/the_automated_daily_hacker_news] Spanish [https://bit.ly/the_automated_daily_hacker_news_es] French [https://bit.ly/the_automated_daily_hacker_news_fr] - AI news * Apple Podcast English [https://apple.co/3M6Tg1o] Spanish [https://apple.co/4315L7Y] French [https://apple.co/3DkZbPb] * Spotify English [https://spoti.fi/3tzOfrz] Spanish [https://spoti.fi/416m40q] French [https://spoti.fi/41HuJGW] * RSS English [https://bit.ly/the_automated_daily_hackernews_ai] Spanish [https://bit.ly/the_automated_daily_hackernews_es_ai] French [https://bit.ly/the_automated_daily_hackernews_fr_ai] Visit our website at https://theautomateddaily.com/ [ https://theautomateddaily.com/] Send feedback to feedback@theautomateddaily.com Youtube [https://www.youtube.com/@TheAutomatedDaily] LinkedIn [https://www.linkedin.com/in/the-automated-daily/] X (Twitter) [https://x.com/automated_daily]

CAR-T clears path for transplants & AI-designed coronavirus vaccine tested - News (Jun 5, 2026)

Please support this podcast by checking out our sponsors: - Invest Like the Pros with StockMVP - https://www.stock-mvp.com/?via=ron [https://www.stock-mvp.com/?via=ron] - Discover the Future of AI Audio with ElevenLabs - https://try.elevenlabs.io/tad [https://try.elevenlabs.io/tad] - Consensus: AI for Research. Get a free month - https://get.consensus.app/automated_daily [https://get.consensus.app/automated_daily] Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily [https://buymeacoffee.com/theautomateddaily] TODAY'S TOPICS: CAR-T CLEARS PATH FOR TRANSPLANTS - ENGINEERED CAR-T CELLS HELPED HIGHLY SENSITIZED KIDNEY PATIENTS RECEIVE TRANSPLANTS BY REDUCING ANTIBODY-DRIVEN REJECTION RISK, POTENTIALLY EXPANDING ACCESS BEYOND DIALYSIS. AI-DESIGNED CORONAVIRUS VACCINE TESTED - CAMBRIDGE RESEARCHERS TESTED AN AI-DESIGNED “SUPER-ANTIGEN” CORONAVIRUS VACCINE CONCEPT IN HUMANS, AIMING FOR BROAD PROTECTION AGAINST FUTURE VARIANTS AND SPILLOVERS. GLP-1 DRUGS AND CANCER SIGNALS - ASCO-PRESENTED STUDIES SUGGEST GLP-1 MEDICINES MAY CORRELATE WITH LOWER CANCER RISK AND IMPROVED OUTCOMES, PROMPTING CALLS FOR RANDOMIZED CLINICAL TRIALS AND CAREFUL SAFETY REVIEW. LENACAPAVIR INJECTION FOR HIV PREVENTION - SOUTH AFRICA IS ROLLING OUT TWICE-YEARLY LENACAPAVIR FOR HIV PREVENTION, A LONG-ACTING PREP OPTION THAT COULD BOOST ADHERENCE AND REDUCE NEW INFECTIONS. EU PUSHES TECH SOVEREIGNTY LAWS - THE EUROPEAN COMMISSION PROPOSED A TECHNOLOGICAL SOVEREIGNTY PACKAGE COVERING CHIPS, CLOUD, AI, AND OPEN SOURCE TO REDUCE DEPENDENCE ON NON-EU SUPPLIERS AND SECURE CRITICAL SERVICES. CANADA’S AI PLAN AND SOVEREIGNTY - CANADA’S NATIONAL AI STRATEGY INCLUDES BILLIONS FOR AI LITERACY, DOMESTIC COMPUTING CAPACITY, AND TALENT RETENTION, WHILE CRITICS SAY SAFETY AND ONLINE PROTECTIONS ARE STILL VAGUE. US–JAPAN AI RESEARCH PARTNERSHIP - JAPAN AND THE US LAUNCHED A $1 BILLION INITIATIVE TO SPEED R&D USING AI, INCLUDING AUTONOMOUS LABS FOR QUANTUM, FUSION, AND BIOTECH, WITH AN EYE ON STRATEGIC COMPETITION. SELF-REPLICATING AI WORM RAISES ALARMS - UNIVERSITY OF TORONTO RESEARCHERS DEMONSTRATED A PROOF-OF-CONCEPT SELF-REPLICATING “AI WORM” THAT ADAPTS EXPLOITS USING A LOCAL LANGUAGE MODEL, HIGHLIGHTING NEW CYBER DEFENSE NEEDS. GOOGLE SEEKS STERILE MOSQUITO RELEASE - GOOGLE ASKED US REGULATORS TO ALLOW LARGE-SCALE RELEASES OF STERILIZED MALE MOSQUITOES CARRYING WOLBACHIA TO REDUCE DISEASE VECTORS, TESTING PUBLIC ACCEPTANCE OF BIOLOGICAL CONTROL. LARGEST COSMIC MAGNETIC FIELD MAP - CSIRO AND SKA OBSERVATORY PARTNERS RELEASED SPICE-RACS, THE BIGGEST MAGNETIC-FIELD MAP OF THE UNIVERSE, ENABLING NEW STUDIES OF GALAXY EVOLUTION AND THE COSMIC WEB. Episode Transcript CAR-T clears path for transplants Let’s start with the medical story that could reshape organ transplantation for a very specific, very vulnerable group of patients. Two independent teams, writing in the New England Journal of Medicine, report that three people with end-stage kidney disease successfully received kidney transplants after a single treatment with engineered CAR-T immune cells. These patients were considered “highly sensitized,” meaning their immune systems carried high levels of antibodies that typically trigger rapid rejection—so high that compatible donors were effectively out of reach and dialysis was the only realistic option. More than a year later, the transplanted kidneys are still functioning, and the clinicians reported no notable side effects in these cases. The key idea is to use a patient’s own modified immune cells to dial down the specific antibody-producing cells that drive rejection risk. It’s early, and it’s only a few patients—but if larger studies confirm this, it could open transplant access for people who’ve been shut out by biology, not by a shortage of donors alone. AI-designed coronavirus vaccine tested Staying in health, researchers at the University of Cambridge say they’ve tested a fundamentally new vaccine concept in humans—one where the central antigen was designed entirely by artificial intelligence. Instead of aiming at one circulating strain, the AI looked across genetic sequences from many coronaviruses and designed a sort of “super-antigen” intended to train immunity across the whole family, including potential future animal-to-human spillovers. In a small early trial of 39 people, the focus was safety, and the immune response was described as modest. Still, the team argues the approach is promising enough to justify a bigger follow-up study of about 200 participants. The bigger idea here is preparedness: if vaccines can be designed to cover broader viral families, the world may not have to play catch-up as often when viruses mutate or jump species. GLP-1 drugs and cancer signals More provocative signals in medicine came out of the American Society of Clinical Oncology meeting, where researchers discussed a growing body of evidence around GLP-1 drugs—best known for diabetes and weight loss—and cancer outcomes. Across more than two dozen mostly observational studies using health records and real-world databases, GLP-1 users appeared to have lower risks for certain cancers and, in some analyses, better outcomes like reduced metastasis and improved survival. One large study in women linked GLP-1 use with a markedly lower breast cancer risk; another found lower odds of metastatic spread in several cancers. Researchers suspect the story could involve inflammation and metabolic effects, not just weight loss. But the caution is just as important: observational signals can be misleading, shaped by differences in who gets these medications and what care they can access. The takeaway is momentum—these patterns are consistent enough that experts are calling for randomized clinical trials to test whether GLP-1s can actually help prevent cancer or improve treatment results. Lenacapavir injection for HIV prevention And in HIV prevention, South Africa is marking a major milestone with the rollout of Lenacapavir, a long-acting injection designed to prevent infection with just two doses a year. President Cyril Ramaphosa is set to officially launch the programme in Secunda, alongside health leaders and international partners. The significance is practical: daily prevention pills work well, but adherence is hard in the real world. A twice-yearly option could widen access and make consistent protection more realistic for more people—especially in a country running the world’s largest HIV treatment programme, where preventing new infections remains essential to ultimately ending the epidemic. EU pushes tech sovereignty laws Now to policy and power: the European Commission has unveiled what it’s calling a European Technological Sovereignty Package, aimed at boosting Europe’s ability to build and control key digital technologies. The plan spans chips, artificial intelligence, cloud computing, and open source software, and it reflects a simple pressure point: rising AI-driven demand for computing, paired with heavy reliance on non-EU suppliers. The Commission’s argument is that reducing these dependencies isn’t just about industry—it’s about resilience for critical services like healthcare systems, energy grids, and digital public services. Whether the package delivers will depend on funding, execution, and how quickly Europe can translate ambition into capacity. Canada’s AI plan and sovereignty Canada is also pushing the idea of “AI sovereignty,” unveiling a national AI strategy for the next decade. Prime Minister Mark Carney framed AI adoption as inevitable and put more than two billion Canadian dollars on the table for AI literacy and faster uptake across business and government. Ottawa wants to build domestic computing muscle, including a secure public supercomputer and more Canadian data centres by 2030, while also trying to slow the talent drain with research funding, university positions, and faster immigration pathways for skilled workers. The plan emphasizes practical areas like healthcare, with money earmarked to cut administrative load and improve diagnostics. The political friction point: critics say the strategy is light on concrete details for AI safety and online protections—exactly the area where public anxiety is highest. US–Japan AI research partnership On the international stage, Japan and the United States announced a five-year, one-billion-dollar joint initiative to accelerate research using AI, with each country contributing half. Japan becomes the first international partner in the US “Genesis Mission” programme, and the collaboration is aimed at advanced fields like quantum technology, nuclear fusion, and biotechnology. A headline element is the push toward AI- and robotics-enabled labs—facilities that can run parts of the research process more continuously and systematically. Beyond the science, there’s geopolitics: officials framed it as a way to maintain a technological edge, with China clearly in the background of that conversation. Self-replicating AI worm raises alarms Now, a story that will make security teams sit up straighter. Researchers at the University of Toronto’s CleverHans Lab say they’ve built a proof-of-concept self-replicating “AI worm” that uses an open-weight language model to adapt as it moves through a network—rather than relying on a fixed, pre-planned playbook. In tests run in an isolated environment, the worm was able to identify vulnerabilities, gain higher levels of access, and spread widely. What’s especially unsettling is the economics: because the model can run locally on compromised machines, it may bypass the kinds of guardrails people associate with hosted AI services, and it can essentially use victims’ computing power to keep going. The researchers say they won’t publicly release the tool, and they’re urging defenses like tighter network segmentation and zero-trust approaches. The larger point is that AI isn’t only speeding up defenders—it can also compress the cost and time required for attackers. Google seeks sterile mosquito release In public health and environmental intervention, Google has asked US regulators for permission to release up to 32 million sterilized mosquitoes in parts of California and Florida over two years. The idea is to reduce populations of disease-carrying mosquitoes using a technique that aims to prevent viable offspring, focusing on male mosquitoes—which don’t bite—while targeting the broader population decline over time. Experts note the method is used in pest management, but scaling it up is hard: mass-producing, transporting, and releasing fragile insects safely is a real logistical challenge. This request is also a test case for oversight and public trust, as private-sector involvement in biological control becomes more visible. Largest cosmic magnetic field map Finally, a quick look up—way up. An international team led by Australia’s CSIRO and the SKA Observatory has released SPICE-RACS, described as the largest map yet of the universe’s magnetic fields, and about five times larger than previous efforts combined. Built using the ASKAP radio telescope in Western Australia, the project tracks how radio waves from distant galaxies are subtly twisted by magnetic fields along their path. The result is a dataset covering millions of galaxies, now publicly available, that scientists say will sharpen research into how magnetic fields influence galaxy growth and the movement of matter through space—including in and around our own Milky Way. It’s one of those infrastructure-like science releases: not a single “answer,” but a tool that can unlock many new questions. Subscribe to edition specific feeds: - Space news * Apple Podcast English [https://apple.co/4cLLrdt] * Spotify English [https://spoti.fi/4jN8Dui] * RSS English [https://bit.ly/the_automated_daily_space] Spanish [https://theautomateddaily.com/space_es/feed.xml] French [https://theautomateddaily.com/space_fr/feed.xml] - Top news * Apple Podcast English [https://apple.co/3PTvdUF] Spanish [https://apple.co/3ECCMgk] French [https://apple.co/4hmcxbB] * Spotify English [https://spoti.fi/3ZYXAW2] Spanish [https://spoti.fi/414h4JD] French [https://spoti.fi/3Di0jDe] * RSS English [https://bit.ly/the_automated_daily_news] Spanish [https://bit.ly/the_automated_daily_news_es] French [https://bit.ly/the_automated_daily_news_fr] - Tech news * Apple Podcast English [https://apple.co/3RYWbg4] Spanish [https://apple.co/4i0WqRM] French [https://apple.co/4bEAXMm] * Spotify English [https://spoti.fi/3S089pG] Spanish [https://spoti.fi/3EE2Fwv] Spanish [https://spoti.fi/3DlObRE] * RSS English [https://bit.ly/the_automated_daily_tech] Spanish [https://bit.ly/the_automated_daily_tech_es] French [https://bit.ly/the_automated_daily_tech_fr] - Hacker news * Apple Podcast English [https://apple.co/48QWyzj] Spanish [https://apple.co/4ke9jtE] French [https://apple.co/41E1qFd] * Spotify English [https://spoti.fi/45zD1kf] Spanish [https://spoti.fi/4hF8h81] French [https://spoti.fi/3QY26Ak] * RSS English [https://bit.ly/the_automated_daily_hacker_news] Spanish [https://bit.ly/the_automated_daily_hacker_news_es] French [https://bit.ly/the_automated_daily_hacker_news_fr] - AI news * Apple Podcast English [https://apple.co/3M6Tg1o] Spanish [https://apple.co/4315L7Y] French [https://apple.co/3DkZbPb] * Spotify English [https://spoti.fi/3tzOfrz] Spanish [https://spoti.fi/416m40q] French [https://spoti.fi/41HuJGW] * RSS English [https://bit.ly/the_automated_daily_hackernews_ai] Spanish [https://bit.ly/the_automated_daily_hackernews_es_ai] French [https://bit.ly/the_automated_daily_hackernews_fr_ai] Visit our website at https://theautomateddaily.com/ [ https://theautomateddaily.com/] Send feedback to feedback@theautomateddaily.com Youtube [https://www.youtube.com/@TheAutomatedDaily] LinkedIn [https://www.linkedin.com/in/the-automated-daily/] X (Twitter) [https://x.com/automated_daily]